~~All responses to this question to be addressed to cocktailtime@yahoo.com
Are Merck shareholders aware of the action of the drugs,
Lovastatin/Onconase, against cancer. Lovastatin is owned by Merck,
FDA approved to treat high cholesterol, but also shows synergism with
another drug called Onconase, owned by a company called Alfacell.
Together, the drugs are very powerful against cancer. Alfacell is
pursuing Onconase alone, their clinical trials have failed, and
they're going broke fast. They have not pursued and are unlikely to
pursue the powerful synergistic affects of Lovastatin/Onconase, if
only because all the money will soon be gone and/Merck owns
Lovastatin, and their shareholders are simply watching the clock tick,
while cancer sufferers are being deprived of a real opportunity for
help in areas of cancer where there is currently no effective
treatment. There is great potential if Merck could grab this "diamond
in the rough", and bring this baby home. There's great, great
potential this would make the world look at protease inhibitors (the
latest things against AIDS) as old fashion medicine, and leave the
other large biotech companies scratching their heads, saying, "how did
we miss this one?" Merck knows as well as anyone that we live in an
era of drug cocktails (it takes 3 to 4 drugs at a time to be
effective against AIDS, among them Merck's, in combination they seem
to knock the hell out of it). Why does Merck seem to be missing this
regarding Lovastatin/Onconase? And what can be done to get them on it? |
